Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
SNTS [NASD]
Santarus, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E44.56 EPS (ttm)0.50 Insider Own1.02% Shs Outstand64.63M Perf Week3.01%
Market Cap1.44B Forward P/E17.27 EPS next Y1.29 Insider Trans-87.88% Shs Float59.80M Perf Month17.02%
Income36.64M PEG2.17 EPS next Q0.17 Inst Own62.68% Short Float4.56% Perf Quarter70.34%
Sales251.52M P/S5.73 EPS this Y261.00% Inst Trans-2.48% Short Ratio2.03 Perf Half Y139.83%
Book/sh1.65 P/B13.50 EPS next Y46.59% ROA23.59% Target Price22.30 Perf Year295.04%
Cash/sh1.51 P/C14.75 EPS next 5Y20.50% ROE44.68% 52W Range4.82 - 24.00 Perf YTD102.91%
Dividend- P/FCF52.61 EPS past 5Y14.49% ROI37.82% 52W High-5.75% Beta1.33
Dividend %- Quick Ratio2.23 Sales past 5Y18.21% Gross Margin65.06% 52W Low369.29% ATR0.92
Employees290 Current Ratio2.39 Sales Q/Q73.15% Oper. Margin15.50% RSI (14)73.71 Volatility4.44% 4.04%
OptionableYes Debt/Eq0.09 EPS Q/Q2480.92% Profit Margin14.57% Rel Volume1.38 Prev Close22.28
ShortableYes LT Debt/Eq0.09 EarningsMay 06 AMC Payout0.00% Avg Volume1.34M Price22.62
Recom1.60 SMA2012.69% SMA5021.77% SMA20084.93% Volume1,283,299 Change1.53%
07-May-13Reiterated Stifel Buy $20 → $22
05-Mar-13Reiterated Stifel Buy $13 → $15
12-Sep-12Reiterated Stifel Nicolaus Buy $8 → $11
02-Dec-09Reiterated Roth Capital Buy $6 → $7
25-Jun-09Initiated Roth Capital Buy $6
16-Dec-08Initiated Piper Jaffray Neutral
05-Aug-08Reiterated UBS Buy $3.70 → $4
10-Mar-08Upgrade UBS Neutral → Buy
02-Nov-07Reiterated RBC Capital Mkts Outperform $5 → $4
02-Nov-07Reiterated Friedman Billings Outperform $6 → $4
10-Aug-07Downgrade UBS Buy → Neutral $7 → $3
07-Aug-07Reiterated RBC Capital Mkts Outperform $9 → $6
06-Aug-07Reiterated Friedman Billings Outperform $7 → $6
02-Jul-07Upgrade Susquehanna Financial Negative → Neutral
29-Jun-07Upgrade Friedman Billings Mkt Perform → Outperform $7
29-Jun-07Initiated Rodman & Renshaw Mkt Outperform $8
24-May-07Upgrade Merriman Curhan Ford Neutral → Buy
06-Mar-07Reiterated RBC Capital Mkts Outperform $10 → $9
14-Feb-07Initiated Friedman Billings Mkt Perform $7
23-May-13 11:35AM  Ironwood Pharma Prices Stock Offering Zacks
08:01AM  The Zacks Analyst Blog Highlights: Zumiez, Mylan, AbbVie, Santarus and Jazz Pharmaceuticals Zacks
22-May-13 06:03PM  Bull of the Day: Santarus at Seeking Alpha
04:30PM  Data on Merck KGaA's L-BLP25 Zacks
04:25PM  Data on UCB's Neupro Zacks
04:20PM  XenoPort Resumes Horizant Supply Zacks
04:10PM  The Retire Young Portfolio: Time To Add A High-Growth Medicine Company at Seeking Alpha
04:00PM  Sanofi/REGN's Dupilumab Data Published Zacks
03:50PM  FDA Designation for Synageva Candidate Zacks
03:35PM  Swiss Issue for AMAG/Takeda's Rienso Zacks
02:55PM  Additional Patent for Acorda's Ampyra Zacks
02:45PM  Generic Launches at Mylan Continue Zacks
10:41AM  Stocks Climb In Mixed Trade; Toll Bros. Up, Target Slumps at Investor's Business Daily
10:40AM  AbbVie Extends Galapagos Deal Zacks
09:06AM  Santarus Is a Real Gas! at Motley Fool
08:27AM  Zacks Bull and Bear of the Day Highlights: Santarus, Nuance Communications, Sprint Nextel, DISH Network and Verizon Communications Zacks
21-May-13 04:10PM  Positive Data on Novo Nordisk's N9-GP Zacks
04:00PM  Actavis to Buy Warner Chilcott Zacks
10:50AM  JNJ's Simponi Label Expanded Zacks
20-May-13 11:00AM  FDA Accepts Actavis NDA Zacks
17-May-13 06:51PM  IBD 50 Stocks Delivering Strong Earnings, Sales Gains at Investor's Business Daily
07:00AM  Santarus Announces UCERIS (budesonide) Poster Presentations at Digestive Disease Week Meeting Business Wire
16-May-13 08:42PM  Santarus' CEO Presents at Bank of America/Merrill Lynch Health Care Conference (Transcript) at Seeking Alpha
01:02AM  Pharming reports on financial results first quarter 2013 Thomson Reuters ONE
15-May-13 05:16PM  Good News for Novartis' Ilaris Zacks
04:05PM  Santarus Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Secondary Common Stock Offering Business Wire
04:00PM  Pediatric Approval for MDCO/BMY's Recothrom Zacks
01:04PM  'Superperformance' Stocks Mid-May Update at Seeking Alpha
11:40AM  Synergy Pharma Posts Wider Loss Zacks
11:40AM  Dr. Reddy's Earnings Increase Y/Y Zacks
14-May-13 03:36PM  Special Dividend and Ongoing Cash Distribution at Motley Fool
02:30PM  2 Biotech Companies With Strong Product Launches To Monitor at Seeking Alpha
11:10AM  Forest-Trevena Ink Deal Zacks
10:20AM  Jazz Pharma Posts Higher Y/Y Earnings Zacks
09:45AM  Salix Beats on Earnings Zacks
09:40AM  Narrower-than-Expected Loss at Supernus Zacks
13-May-13 03:45PM  Wider-Than-Expected Loss at Anacor Zacks
03:45PM  Teva - Alexza Sign Deal for Adasuve Zacks
02:14PM  Pernix Reports Loss in 1Q Zacks
01:50PM  2 Stocks with Weakness that are Definite Buys at Motley Fool
11:00AM  Lilly Scraps Oncology Candidate Zacks
08:41AM  Narrower-than-Expected Loss at MannKind Zacks
11-May-13 01:04PM  SANTARUS INC Financials EDGAR Online Financials
11:11AM  The First Step in Treating Type 2 Diabetes at Motley Fool
08:06AM  Actavis Joins Other Drugmakers On Elite IBD 50 at Investor's Business Daily
10-May-13 11:30AM  Simcere Beats 1Q Earnings & Revenue Estimate Zacks
10:32AM  SANTARUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
09:15AM  Pacira Reports Wider Loss Zacks
09:05AM  InPlay: Santarus announces pricing of secondary common stock offering of $18.25 per share for 4.25 mln shares by selling stockholder Cosmo Technologies Briefing.com
09:04AM  Santarus Announces Pricing of Secondary Common Stock Offering by a Selling Stockholder Business Wire
09-May-13 04:02PM  InPlay: Santarus announces proposed secondary common stock offering by a selling stockholder; size not disclosed Briefing.com
04:01PM  Santarus Announces Launch of a Proposed Secondary Common Stock Offering by a Selling Stockholder Business Wire
03:30PM  Positive Data on Celgene's Apremilast Zacks
11:48AM  Review Of Depomed First Quarter 2013 Results at Seeking Alpha
09:10AM  Wider-than-Expected Loss at Avanir Zacks
08-May-13 04:30PM  Santarus Beats on Earnings and Revs Zacks
03:46PM  2 Tech Stocks And 1 Biotech With Recent Intensive Insider Selling at Seeking Alpha
10:15AM  Ariad Posts Wider Y/Y Loss Zacks
09:07AM  Two Different Outlooks With Similar Growth Plans at Motley Fool
09:00AM  Earnings News Drags On Futures; Whole Foods Market Bolts Higher at Investor's Business Daily
08:55AM  Santarus CEO Sells More Than 86K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
07-May-13 09:19PM  Santarus Beats on Both Top and Bottom Lines at Motley Fool +10.65%
06:02PM  Nasdaq stocks posting largest percentage increases AP
03:31PM  Santarus climbs on 1Q report and new guidance AP
03:01PM  Nasdaq stocks posting largest percentage increases AP
12:25PM  Why Santarus Shares Soared at Motley Fool
12:00PM  Wider-than-Expected Loss at Corcept Zacks
11:27AM  Santarus Stock Lifts Off On Q1 Earnings, Guidance at Investor's Business Daily
09:03AM  Futures Aim Moderately Higher; MercadoLibre, Nationstar Rising at Investor's Business Daily
09:02AM  Stocks to Watch: Ruckus, Aruba Networks, Santarus at The Wall Street Journal
06-May-13 09:32PM  Santarus CEO Discuses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha
06:56PM  On The Fly: After Hours Movers at theflyonthewall.com
05:56PM  Santarus Earnings Trounce Estimates; Stock Hits High at Investor's Business Daily
05:22PM  Santarus Earnings: Heres Why Investors are Happy Now at Wall St. Cheat Sheet
04:44PM  BRIEF-Santarus up 12.6 percent in extended trade after Q1 results, outlook at Reuters
04:05PM  Santarus Reports First Quarter 2013 Financial Results Business Wire
09:15AM  SANTARUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:07AM  Q1 2013 Santarus Inc. Earnings Release - After Market Close CCBN
03-May-13 07:00AM  Santarus to Present at May and June Investment Conferences Business Wire
02-May-13 12:09PM  2 Biotechs Primed For Prosperity In 2013 at Seeking Alpha
07:25AM  Santarus' Cycloset included in comprehensive diabetes management algorithm theflyonthewall.com
07:03AM  InPlay: Santarus: CYCLOSET (bromocriptine mesylate) included in American Association of Clinical Endocrinologists comprehensive diabetes management algorithm Briefing.com
07:00AM  CYCLOSET (bromocriptine mesylate) Included in American Association of Clinical Endocrinologists Comprehensive Diabetes Management Algorithm Business Wire
01-May-13 08:02AM  Five Top-Rated Young Gun Stocks With Earnings On Tap at Investor's Business Daily
30-Apr-13 08:06AM  The Zacks Analyst Blog Highlights: Merck, GlaxoSmithKline, VIVUS, Santarus and Celgene Zacks
29-Apr-13 03:30PM  Merck Likely to Beat 1Q Earnings Zacks
11:25AM  FDA Loosening Restrictions and Companies More Diligent in Producing Data the FDA Wants: An Expert Analyst Discusses Drivers in the Favorable Regulatory Environment with The Wall Street Transcript Wall Street Transcript
22-Apr-13 04:26PM  3 Stocks You Should Avoid at Motley Fool
07:00AM  Santarus to Hold First Quarter 2013 Financial Results Conference Call on May 6 Business Wire
18-Apr-13 04:10PM  Santarus to Make Cash Milestone Payment Zacks
17-Apr-13 09:16AM  SANTARUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
01:21AM  InPlay: Santarus and Pharming Group submit BLA to FDA to obtain marketing approval for RUCONEST Briefing.com
01:02AM  Pharming and Santarus announce submission of RUCONEST Biologics License Application to FDA Thomson Reuters ONE
01:00AM  Santarus and Pharming Announce Submission of RUCONEST Biologics License Application to FDA Business Wire
16-Apr-13 09:12AM  SANTARUS INC Files SEC form 8-K, Other Events EDGAR Online +5.78%
08:05AM  Top 5 Earnings Estimate Beaters Prove Experts Wrong at Investor's Business Daily
11-Apr-13 06:29PM  Santarus CEO Hosts Analyst Day (Transcript) at Seeking Alpha
09:32AM  SANTARUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
10-Apr-13 12:14PM  1 Electronics Store, 1 Biotech And An Energy Company With Recent Intensive Insider Selling at Seeking Alpha
10:00AM  Santarus, Inc. [SNTS] to Ring The NASDAQ Stock Market Closing Bell GlobeNewswire
Santarus, Inc., a specialty biopharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. The company offers Uceris extended release tablets for the induction of remission in active, mild to moderate ulcerative colitis; Zegerid to treat certain upper gastrointestinal conditions; and Fenoglide fenofibrate tablets marketed as an adjunct to diet to treat high cholesterol It also provides Glumetza metformin hydrochloride extended release tablets and Cycloset bromocriptine mesylate tablets marketed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. In addition, the company focuses on advancing investigational drugs to commercialization, including Ruconest, a recombinant human C1 esterase inhibitor that has completed Phase III clinical study for treatment of acute attacks of angioedema in patients with hereditary angioedema; Rifamycin SV MMX, which has completed Phase III clinical study for treatment of travelers' diarrhea; and SAN-300, an anti-VLA-1 antibody that has completed a Phase I dose-escalation clinical study for the treatment of rheumatoid arthritis. Santarus, Inc. has strategic alliance agreements with MSD Consumer Products, Inc. and Glaxo Group Limited. The company was founded in 1996 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cosmo Technologies Ltd10% OwnerMay 15Sale17.684,887,50086,387,0512,991,044May 15 04:14 PM
Della Cha AlessandroDirectorMay 15Sale21.3316,500351,95049,715May 17 05:07 PM
HERMAN MICHAEL EDirectorMay 14Sale20.7725,000519,33350,000May 15 06:38 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasMay 10Option Exercise3.5018,64365,251184,607May 13 04:39 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasMay 10Sale19.2718,643359,182165,964May 13 04:39 PM
DE MEULES JULIE ASr. VP, Human ResourcesMay 09Option Exercise5.2511,64761,14716,595May 10 04:34 PM
DE MEULES JULIE ASr. VP, Human ResourcesMay 09Sale20.1015,165304,7571,430May 10 04:34 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAMay 08Option Exercise1.8510,00018,48858,593May 09 05:46 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAMay 08Sale20.5310,000205,34448,593May 09 05:46 PM
Fox Carey JSr VP, General CounselMay 07Option Exercise1.1817,10020,17841,234May 08 07:11 PM
Fox Carey JSr VP, General CounselMay 07Sale20.8617,100356,78124,134May 08 07:11 PM
PROEHL GERALD TPresident & CEOMay 06Option Exercise0.8886,60375,778160,740May 07 09:09 PM
Step Michael DSVP, Corporate DevelopmentMay 06Option Exercise1.1830,30135,75531,798May 07 09:12 PM
Step Michael DSVP, Corporate DevelopmentMay 06Sale18.7430,301567,7011,497May 07 09:12 PM
PROEHL GERALD TPresident & CEOMay 06Sale18.7386,6031,622,46474,137May 07 09:09 PM
HALL WARREN ESr. VP, Mfg. & Prod. Dev.May 03Option Exercise3.5027,89497,62938,440May 06 09:35 PM
HALL WARREN ESr. VP, Mfg. & Prod. Dev.May 03Sale18.8928,749543,0749,691May 06 09:35 PM
Ballard E David IISVP, Med Affairs & Pharm'vigMay 02Option Exercise1.189,00010,6209,000May 03 04:56 PM
Ballard E David IISVP, Med Affairs & Pharm'vigMay 02Sale18.459,000166,0270May 03 04:56 PM
BURGESS DANIEL DDirectorMay 01Option Exercise3.008,00024,0008,000May 02 04:24 PM
DENBY WILLIAM CSr. VP, Commercial OperationsMay 01Option Exercise3.5019,59868,59324,450May 02 04:28 PM
DENBY WILLIAM CSr. VP, Commercial OperationsMay 01Sale17.9024,450437,6230May 02 04:28 PM
BURGESS DANIEL DDirectorMay 01Sale17.888,000143,0470May 02 04:24 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasApr 10Option Exercise3.5019,00066,500184,964Apr 11 05:15 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasApr 10Sale16.8219,000319,563165,964Apr 11 05:15 PM
DE MEULES JULIE ASr. VP, Human ResourcesApr 09Option Exercise5.2515,16579,61620,113Apr 10 04:20 PM
DE MEULES JULIE ASr. VP, Human ResourcesApr 09Sale17.0615,165258,7574,948Apr 10 04:20 PM
Fox Carey JSr VP, General CounselApr 08Option Exercise1.1817,10020,17841,234Apr 09 06:45 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAApr 08Option Exercise1.1810,00011,80058,593Apr 09 06:47 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAApr 08Sale16.7010,000167,03048,593Apr 09 06:47 PM
Fox Carey JSr VP, General CounselApr 08Sale16.6917,100285,38024,134Apr 09 06:45 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAApr 05Option Exercise3.0442,744129,94848,593Apr 09 06:47 PM
PROEHL GERALD TPresident & CEOApr 04Option Exercise0.8886,60175,776544,308Apr 05 04:25 PM
PROEHL GERALD TPresident & CEOApr 04Sale16.7586,6011,450,151457,707Apr 05 04:25 PM
Ballard E David IISVP, Med Affairs & Pharm'vigApr 02Option Exercise1.1818,00021,24018,000Apr 03 05:03 PM
Ballard E David IISVP, Med Affairs & Pharm'vigApr 02Sale17.8918,000322,0920Apr 03 05:03 PM
BURGESS DANIEL DDirectorApr 01Option Exercise2.098,00016,7208,000Apr 02 05:26 PM
DENBY WILLIAM CSr. VP, Commercial OperationsApr 01Option Exercise0.883,0462,66529,302Apr 02 05:29 PM
DENBY WILLIAM CSr. VP, Commercial OperationsApr 01Sale17.7524,450433,9954,852Apr 02 05:29 PM
BURGESS DANIEL DDirectorApr 01Sale17.478,000139,7740Apr 02 05:26 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasMar 11Option Exercise3.5019,00066,500184,964Mar 12 04:57 PM
DE MEULES JULIE ASr. VP, Human ResourcesMar 11Option Exercise5.2515,16579,61620,113Mar 12 04:59 PM
DE MEULES JULIE ASr. VP, Human ResourcesMar 11Sale15.3815,165233,1694,948Mar 12 04:59 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasMar 11Sale15.4419,000293,373165,964Mar 12 04:57 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAMar 08Option Exercise1.1810,00011,80015,849Mar 11 04:39 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAMar 08Sale15.4710,000154,6995,849Mar 11 04:39 PM
Fox Carey JSr VP, General CounselMar 07Option Exercise1.4217,10024,35441,234Mar 07 04:49 PM
HERMAN MICHAEL EDirectorMar 07Option Exercise3.2140,000128,250115,000Mar 07 04:53 PM
HERMAN MICHAEL EDirectorMar 07Sale15.2745,000687,04216,000Mar 07 04:53 PM
Fox Carey JSr VP, General CounselMar 07Sale15.2517,100260,73924,134Mar 07 04:49 PM
CARTER MICHAEL GDirectorMar 07Sale15.2232,000487,0400Mar 08 04:11 PM
Step Michael DSVP, Corporate DevelopmentMar 05Option Exercise1.188,94910,56031,798Mar 06 06:03 PM
Step Michael DSVP, Corporate DevelopmentMar 05Sale15.4530,301468,0991,497Mar 06 06:03 PM
Ballard E David IISVP, Med Affairs & Pharm'vigMar 04Option Exercise1.1818,00021,24018,000Mar 05 06:40 PM
HALL WARREN ESr. VP, Mfg. & Prod. Dev.Mar 04Option Exercise3.5028,749100,62239,295Mar 05 06:43 PM
PROEHL GERALD TPresident & CEOMar 04Option Exercise0.8886,60175,776544,308Mar 05 06:46 PM
PROEHL GERALD TPresident & CEOMar 04Sale13.5786,6011,174,803457,707Mar 05 06:46 PM
HALL WARREN ESr. VP, Mfg. & Prod. Dev.Mar 04Sale13.5728,749390,06910,546Mar 05 06:43 PM
Ballard E David IISVP, Med Affairs & Pharm'vigMar 04Sale13.5818,000244,4810Mar 05 06:40 PM
BURGESS DANIEL DDirectorMar 01Option Exercise1.188,0009,4408,000Mar 04 08:07 PM
DENBY WILLIAM CSr. VP, Commercial OperationsMar 01Option Exercise0.8824,45021,39450,706Mar 04 08:13 PM
DENBY WILLIAM CSr. VP, Commercial OperationsMar 01Sale13.3824,450327,16526,256Mar 04 08:13 PM
BURGESS DANIEL DDirectorMar 01Sale13.378,000106,9540Mar 04 08:07 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasFeb 11Option Exercise0.8817,85315,621183,817Feb 12 04:14 PM
DE MEULES JULIE ASr. VP, Human ResourcesFeb 11Option Exercise5.2515,16579,61620,113Feb 12 04:19 PM
DE MEULES JULIE ASr. VP, Human ResourcesFeb 11Sale13.0515,165197,8594,948Feb 12 04:19 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasFeb 11Sale12.9917,853231,941165,964Feb 12 04:14 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAFeb 08Option Exercise1.1810,00011,80015,849Feb 11 04:36 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAFeb 08Sale12.9910,000129,9075,849Feb 11 04:36 PM
Fox Carey JSr VP, General CounselFeb 07Option Exercise2.4817,30042,85241,434Feb 08 05:02 PM
Fox Carey JSr VP, General CounselFeb 07Sale12.7917,300221,24524,134Feb 08 05:02 PM
HERMAN MICHAEL EDirectorFeb 07Sale12.7522,260283,91775,000Feb 08 04:59 PM
HERMAN MICHAEL EDirectorFeb 06Sale12.9767,740878,89397,260Feb 08 04:59 PM
Ballard E David IISVP, Med Affairs & Pharm'vigFeb 04Option Exercise1.1818,00021,24018,000Feb 05 04:17 PM
PROEHL GERALD TPresident & CEOFeb 04Option Exercise0.8886,60175,776544,308Feb 05 04:23 PM
Ballard E David IISVP, Med Affairs & Pharm'vigFeb 04Sale12.9818,000233,6170Feb 05 04:17 PM
PROEHL GERALD TPresident & CEOFeb 04Sale12.9886,6011,123,787457,707Feb 05 04:23 PM
BURGESS DANIEL DDirectorFeb 01Option Exercise1.188,0009,4408,000Feb 04 04:41 PM
DENBY WILLIAM CSr. VP, Commercial OperationsFeb 01Option Exercise0.8824,45021,39450,706Feb 04 04:44 PM
DENBY WILLIAM CSr. VP, Commercial OperationsFeb 01Sale13.3424,450326,18726,256Feb 04 04:44 PM
BURGESS DANIEL DDirectorFeb 01Sale13.288,000106,2450Feb 04 04:41 PM
LOVE TED WDirectorDec 18Buy10.88185,0002,012,800335,500Dec 19 04:09 PM
HALE DAVID FDirectorDec 12Option Exercise2.2584,000188,580304,452Dec 13 04:35 PM
CARTER MICHAEL GDirectorOct 25Option Exercise1.1832,00037,76032,000Oct 26 05:23 PM
HERMAN MICHAEL EDirectorSep 13Option Exercise3.002,0006,000165,000Sep 13 07:48 PM
HERMAN MICHAEL EDirectorSep 12Option Exercise2.4642,000103,290163,000Sep 13 07:48 PM
DE MEULES JULIE ASr. VP, Human ResourcesJun 05Option Exercise2.366,00014,16010,709Jun 06 04:31 PM
DE MEULES JULIE ASr. VP, Human ResourcesJun 05Sale6.806,00040,7864,709Jun 06 04:31 PM
open in yahoo | open in reuters | open in google